VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Thomas Yau(Queen Mary Hospital), Ann‐Lii Cheng(National Taiwan University Hospital), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Shukui Qin(Nanjing University of Chinese Medicine), Andrew X. Zhu(Harvard University), Stephen L. Chan(Chinese University of Hong Kong), Wattana Sukeepaisarnjaroen(Khon Kaen University), В. В. Бредер(Russian Cancer Research Center NN Blokhin), Gontran Verset(Université Libre de Bruxelles), Edward Gane(Auckland City Hospital), Ivan Borbath(Cliniques Universitaires Saint-Luc), J.D. Gomez Rangel, Philippe Merle(Hôpital de la Croix-Rousse), Fawzi Benzaghou, Kamalika Banerjee(Exelixis (United States)), Saswati Hazra(Exelixis (United States)), Jonathan W. Fawcett(Exelixis (United States)), Lorenza Rimassa(Humanitas University)
Cited by 84
Abstract
Related Papers
No related papers found
Powered by citation graph analysis